The autosomal dominant optic atrophy treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and R&D in precision medicine from key ...

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You accept for the main domain ...

Ultimately, Stoke Therapeutics is that classic “intriguing biotech” --hurdling to one of those proverbial “moments of truth” ...

PKD is a genetic disorder marked by kidney cysts and progressive damage. Discover the science, treatment guidelines, and research driving future care.

Autosomal dominant polycystic kidney disease (ADPKD), caused by mutations in the PKD1 or PKD2 genes, is among the most common human monogenic disorders and a leading cause of end-stage renal disease.

It is caused predominantly by genetic changes (mutations) in the UMOD and MUC1 genes. Because of the inheritance pattern (autosomal dominant), a child of an affected parent has a 50% chance of ...

Unknown etiology is commonly encountered in the kidney pre-transplant routine program. A screening program was performed to detect patients and study recipients that meet the following features: ...

Together, the set nailed mutation status with an AUC of 0.89 ... “The findings suggest that, unlike late-life dementia syndromes, the proteomic signature for autosomal dominant AD is largely ...

It’s caused by autosomal dominant mutations in the DMPK or CNBP gene. “Autosomal” means the gene is located on one of the chromosomes not related to sex. “Dominant” means that you need ...

SiSaf Ltd, an RNA delivery and therapeutics company, announces that SIS-101-ADO, its siRNA therapeutic for patients with Autosomal Dominant Osteopetrosis Type 2, has been granted Orphan Drug ...